ElsaLys Biotech spins out of Transgene, raises €2.1mm in Series A round
Immunotherapeutics company Transgene SA (majority owned by Institut Merieux) has spun out ElsaLys Biotech, and participated in the monoclonal antibody firm’s €2.1mm ($2.7mm) Series A round, which also included Sofimac Partners.
- Large Molecule
- Venture Financing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.